MedPal AI (MPAL) has conditionally raised £3 million through a placing to support its expansion and progress towards profitability. The fundraising was completed at 2.5 pence per share, representing a 13% discount to the previous closing price.
The placing, arranged by OAK Securities, saw strong participation from new institutional investors, reflecting confidence in the company’s operational momentum and commercial pipeline. Proceeds will primarily be used to scale its private weight-loss clinic, expand working capital, and support team growth.
Meanwhile, MedPal continues to see rapid growth in NHS dispensing volumes, with a record 41,600 items processed in March 2026. The company is also expanding its care home portfolio and progressing multiple commercial partnerships currently under discussion.
Part of the funding will complete the expansion of robotic dispensing capacity at its Runcorn facility, while also strengthening the balance sheet and providing flexibility for further strategic opportunities.
Following admission of the new shares, expected on 22 April 2026, the company’s total issued share capital will increase to 612,441,036 shares.
MedPal AI’s Chief Executive Jason Drummond said: “This £3 million fundraise is a significant milestone for MedPal. It substantially strengthens our balance sheet and positions us to capitalise on the extraordinary growth we are seeing across every part of our business.
Our NHS pharmacy operations are dispensing at record volumes, our weight-loss clinic is scaling rapidly with the backing of direct supply agreements with Eli Lilly and Novo Nordisk, and our consumer app and clinical triage platform, MedPal Health OS, is attracting significant commercial interest. We have a number of material commercial conversations in progress which this funding will enable us to convert and deliver.
I would like to thank our existing shareholders for their continued support and welcome our new investors. We are also delighted to welcome OAK Securities as joint broker. Their institutional reach and conviction in our strategy will be invaluable as we move into the next phase of growth.”
View from Vox
This placing gives MedPal the financial runway to accelerate across several high-growth areas, particularly in GLP-1 weight-loss treatments and NHS dispensing. With strong demand already evident and multiple commercial discussions underway, the focus now shifts to execution and converting pipeline into revenue as the company moves closer to profitability.